Tomuzotuximab

Modify Date: 2024-04-06 12:39:30

Tomuzotuximab structure	Common Name	Tomuzotuximab
	CAS Number	1646321-00-7	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Tomuzotuximab

Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody against EGFR. Tomuzotuximab has anticancer effects[1].

Name	Tomuzotuximab

Description	Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody against EGFR. Tomuzotuximab has anticancer effects[1].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> EGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR
In Vitro	Tomuzotuximab has a fully human glycosylation pattern and is glyco-optimised at its Fc domain, while fully retaining the affinity, specificity, EGFR inhibition and induction of apoptosis of Cetuximab[1].
References	[1]. Waer Fiedler, et al. Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas. ESMO Open. 2018 Feb 1;3(2):e000303.

No Any Chemical & Physical Properties